Defining a gene promoter methylation signature in sputum for lung cancer risk assessment

Clinical Cancer Research

Volumn 18, Issue 12, 2012, Pages 3387-3395

  Leng, Shuguang ^a   Do, Kieu ^a   Yingling, Christin M ^a   Picchi, Maria A ^a   Wolf, Holly J ^c   Kennedy, Timothy C ^c   Feser, William J ^c   Baron, Anna E ^c   Franklin, Wilbur A ^c   Brock, Malcolm V ^d   Herman, James G ^d   Baylin, Stephen B ^d   Byers, Tim ^c   Stidley, Christine A ^b   Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR PAX5;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GATA5 GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PAX5 ALPHA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPUTUM; SULF2 GENE; UNITED STATES;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DNA METHYLATION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; SPUTUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84862572356     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3049     Document Type: Article

References (31)

1. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
2. Belinsky SA. Gene promoter hypermethylation as a biomarker in lung cancer. Nat Rev 2004;4:707-17. (Pubitemid 39215069)
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92. (Pubitemid 46273572)
4. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891-96.
5. Licchesi JD, Westra WH, Hooker CM, Herman JG. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 2008;14:2570-78.
6. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;5:963-8.
7. Herman JG, Graff J, Myohannen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-26. (Pubitemid 26296693)
8. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-58.
9. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
10. Prindiville SA, Byers T, Hirsch FR, Franklin WA, Miller YE, Vu KO, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003;12:987-93. (Pubitemid 37310253)
11. Kennedy TC, Proudfoot SP, Piantadosi S, Wu L, Saccomanno G, Petty TL, et al. Efficacy of two sputum collection techniques in patients with air flow obstruction. Acta Cytol 1999;43:630-6. (Pubitemid 29364462)
12. Leng S, Stidley C, Willink R, Bernauer A, Do K, Picchi M, et al. Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Res 2008;68:3049-56. (Pubitemid 351556307)
13. Stidley CA, Picchi MA, Leng S, Willink R, Crowell RE, Flores KG, et al. Multi-vitamins, folate, and vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res 2010;70:568-74.
14. Tessema M, Yang YY, Stidley C, Machida EO, Schuebel KE, Baylin SB. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former, and never smokers. Carcinogenesis 2009;30:1132-8.
15. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008;29:895-904. (Pubitemid 351982232)
16. Palmisano WA, Crume KP, Grimes MJ, Winters SA, Toyota M, Esteller M, et al. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003;63:4620-5. (Pubitemid 36951039)
17. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, et al. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 2004;10:7917-24. (Pubitemid 39587531)
18. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative Methylation-specific PCR. Clin Cancer Res 2010;16:3463-72.
19. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-37. (Pubitemid 351483367)
20. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15qq25.1. Nat Genet 2008;40:616-22. (Pubitemid 351601203)
21. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008;40:1407-09.
22. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008;40:1404-6.
23. Kohno T, Kunitoh H, Shimada Y, Shiraishi K, Ishii Y, Goto K, et al. Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 2010;31:834-41.
24. Tessema M, Klinge DM, Yingling CM, Do K, van Neste L, Belinsky SA. Re-expression of the CXCL14 chemokine, a common target for epigenetic silencing in lung cancer induces tumor necrosis. Oncogene 2010;29:5159-70.
25. Leng S, Stidley CA, Liu Y, Edlund CK, Willink RP, Han Y, et al. Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. Cancer Res 2012;72:707-15.
26. Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, et al. Promoter Methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 2005;11:2954-61. (Pubitemid 40525198)
27. Varella-Garcia M, Schulte AP, Wolf HJ, Fesesr WJ, Zeng C, Sraudrick S, et al. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev Res 2010;3:447-453.
28. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2001;108:3713-18.
29. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thoracic Oncol 2011;6:482-88.
30. Qui J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-66.
31. Gower AC, Stelling K, Brothers JF, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc 2011;8:173-79.